

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Hansoh Pharmaceutical Group Company Limited**  
**翰森製藥集團有限公司**  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 3692)

**VOLUNTARY ANNOUNCEMENT**

**LICENSING AGREEMENT WITH NIKANG THERAPEUTICS**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on May 2, 2022 (EST), Hansoh (Shanghai) Healthtech Company Ltd.\* (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Ltd.\* (江蘇豪森藥業集團有限公司) (collectively, the “**Licensees**”), both wholly-owned subsidiaries of the Company, entered into an exclusive license agreement (the “**Licensing Agreement**”) with NiKang Therapeutics Inc. (“**NiKang Therapeutics**”).

Pursuant to the Licensing Agreement, the Licensees obtained an exclusive license from NiKang Therapeutics to develop and commercialize NKT2152 for the treatment of cancer within China (including Hong Kong, Macau and Taiwan). The Licensees will be responsible for the development, regulatory approval and commercialization of NKT2152 in China, and will pay a US\$15 million upfront payment and potential payments upon reaching development, regulatory and sales-based commercial milestones of up to US\$203 million, plus tiered royalties on net sales.

NKT2152 is a small molecule that inhibits HIF-2 $\alpha$ . It is currently in a phase 1/2 dose escalation and expansion trial (NCT05119335). This trial is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced Clear Cell Renal Cell Carcinoma (ccRCC).

NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines. To the best knowledge and belief of the Company, NiKang Therapeutics is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under Listing Rules.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, May 3, 2022

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* For identification purposes only